Board Change

Summary by AI ^BETAClose X

Verici Dx Plc announced that Non-Executive Director James McCullough has resigned from the Board with immediate effect to focus on his CEO role at Renalytix plc, and the company has commenced its search for a replacement.

Disclaimer*

Verici Dx PLC

31 March 2026

Verici Dx plc

("Verici Dx" or the "Company")

Board Change

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that James McCullough, Non-Executive Director, has resigned from the Board with immediate effect to focus on his role as CEO of Renalytix plc.

The Company has begun its search for a replacement Non-Executive Director to join the Board and will provide an update in due course.

Sara Barrington, Chief Executive Officer, said: "It has been a pleasure to work alongside James for the last five years and I would like to thank James for his expertise, advice and contribution to the Company. I wish James every success and all the best for the future."

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR

Singer Capital Markets (Nominated adviser, Joint Broker)		Tel: +44 (0)20 7496 3000
Phil Davies

Oberon Capital (Joint Broker)	Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock

Walbrook PR (Media & Investor Relations)	Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Rachel Broad	Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END